These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25104286)

  • 21. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.
    Yu J; Shi Z; Ji C; Lian Y; Wang Y; Chen L; Mao Y
    Int J Neurosci; 2017 Oct; 127(10):873-880. PubMed ID: 27929688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping genetic factors in high-grade glioma patients.
    Yuan Y; Yunhe M; Xiang W; Yanhui L; Ruofei L; Jiewen L; Qing M
    Clin Neurol Neurosurg; 2016 Nov; 150():159-163. PubMed ID: 27668860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945.
    Eisenstat DD; Pollack IF; Demers A; Sapp MV; Lambert P; Weisfeld-Adams JD; Burger PC; Gilles F; Davis RL; Packer R; Boyett JM; Finlay JL
    J Neurooncol; 2015 Feb; 121(3):573-81. PubMed ID: 25431150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p14ARF promoter region methylation as a marker for gliomas diagnosis.
    He J; Qiao JB; Zhu H
    Med Oncol; 2011 Dec; 28(4):1218-24. PubMed ID: 20714943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-associated brain regions in gliomas: a volumetric analysis.
    Wang Y; Liu S; Fan X; Li S; Wang R; Wang L; Ma J; Jiang T; Ma W
    J Neurooncol; 2015 Jun; 123(2):299-306. PubMed ID: 25981802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
    Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
    J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MRI features predict p53 status in lower-grade gliomas via a machine-learning approach.
    Li Y; Qian Z; Xu K; Wang K; Fan X; Li S; Jiang T; Liu X; Wang Y
    Neuroimage Clin; 2018; 17():306-311. PubMed ID: 29527478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF Inhibition in
    Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
    J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas.
    Gillet E; Alentorn A; Doukouré B; Mundwiller E; van Thuijl HF; Reijneveld JC; Medina JA; Liou A; Marie Y; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Idbaih A
    J Neurooncol; 2014 May; 118(1):131-9. PubMed ID: 24590827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.
    Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D
    J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor microRNA-335 expression is associated with poor prognosis in human glioma.
    Jiang J; Sun X; Wang W; Jin X; Bo X; Li Z; Bian A; Jiu J; Wang X; Liu D; Hui X; Wang Y; Wang A; Ding L
    Med Oncol; 2012 Dec; 29(5):3472-7. PubMed ID: 22644918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of microRNA-504 is associated with poor prognosis in high-grade glioma.
    Guan Y; Chen L; Bao Y; Pang C; Cui R; Li G; Liu J; Wang Y
    Int J Clin Exp Pathol; 2015; 8(1):727-34. PubMed ID: 25755767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas.
    Zou H; Wen C; Peng Z; Shao YΥ; Hu L; Li S; Li C; Zhou HH
    Oncol Rep; 2018 Feb; 39(2):501-510. PubMed ID: 29207176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.
    Alentorn A; Marie Y; Carpentier C; Boisselier B; Giry M; Labussière M; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Idbaih A
    Neuro Oncol; 2012 Nov; 14(11):1393-403. PubMed ID: 23074200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Over-expression of wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas.
    Liang C; Guo E; Lu S; Wang S; Kang C; Chang L; Liu L; Zhang G; Wu Z; Zhao Z; Ma S; Wang L; Jiao BH
    Brain Res; 2012 Mar; 1444():65-75. PubMed ID: 22325093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.